In the IRONMAN trial of 1,137 patients with heart failure and iron deficiency, intravenous ferric derisomaltose lowered recurrent heart failure admissions and cardiovascular death against usual care (rate ratio 0.82), short of statistical significance except in a pre-specified COVID-19 sensitivity analysis.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Ferric derisomaltose (iron isomaltoside 1000)' with aliases Monoferric, Monofer, iron isomaltoside 1000, ferric derisomaltose · 2026-09-27 12:04 · somebody
kind set kind set to mineral: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: In the IRONMAN trial of 1,137 patients with heart failure and iron deficiency, intravenous ferric derisomaltose lowered · 2026-09-27 12:04 · somebody
fact added summary: In two randomized trials in iron-deficiency anemia, hypophosphatemia followed iron isomaltoside (now called ferric deris · 2026-09-27 12:04 · somebody
citation added pmid 36347265 cited as established: Ferric derisomaltose in heart failure with iron deficiency (IRONMAN RCT) · 2026-09-27 12:04 · somebody
citation added pmid 32016310 cited as established: Iron isomaltoside causes much less hypophosphatemia than ferric carboxymaltose (two RCTs) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.